June 2026: Biotech & Pharma NEWS Roundup

Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026!

This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped capital for late-stage security while doubling down on early-stage, high-tech innovation. From AbbVie’s multi-billion-dollar immunology power play to a flurry of high-stakes partnerships involving AI-native drug discovery and novel protein-degradation platforms, the industry spent June 2026 signaling a clear preference for integrated precision, prioritizing assets that can bypass traditional resistance mechanisms and redefine standards of care in oncology and metabolic disease.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, and a storyteller by choice. 

Due to continued demand, I’m reporting monthly episodes for biotech and pharma news. Each monthly recap for news is released on the first day of every month and my goal is to deliver digestible pieces of news on pharma and biotech companies in under 15 mins.

Grab your coffee or tea cuz you’re in for a treat! 

I. Strategic Consolidations & Deals

1. AbbVie’s $10.9B Acquisition of Apogee (https://www.fiercebiotech.com/biotech/abbvie-inks-109b-apogee-buyout-bag-hotly-tipped-eczema-prospect): In one of the month’s largest moves, AbbVie has secured Apogee Therapeutics for $10.9 billion. This acquisition is a strategic "double-down" on its immunology powerhouse status, specifically targeting next-generation biologics for atopic dermatitis and asthma to defend its market share against emerging competitors.
2. Servier’s $2.6B Edgewise Buyout (https://www.fiercebiotech.com/biotech/servier-inks-265b-buyout-edgewises-muscular-dystrophy-unit-beef-neurology-pipeline): Servier is aggressively beefing up its neurology and muscular disorder pipeline by acquiring Edgewise’s muscular dystrophy unit. This move signals the firm's intent to diversify its commercial portfolio beyond its traditional strongholds and capture high-value, orphan-drug indications.
3. Incyte’s $2B Star Therapeutics Deal (https://www.fiercebiotech.com/biotech/incyte-inks-2b-deal-add-star-unit-late-phase-constellation-and-challenge-takeda): In a move to offset the looming 2028 patent expiration of its blockbuster Jakafi, Incyte has moved to acquire Star Therapeutics. The deal provides Incyte with late-stage assets for rare blood disorders, marking a significant strategic pivot under new leadership to stabilize future revenue.
4. Biogen’s $1B RayThera Buyout (https://www.fiercebiotech.com/biotech/biogen-inks-1b-raythera-buyout-bag-preclinical-immunology-assets): Biogen has expanded its immunology footprint by snapping up RayThera. By acquiring this pipeline of preclinical anti-inflammatory candidates, Biogen is signaling a return to its roots of high-science innovation, aiming to build a more diverse, long-term pipeline beyond its core neurology focus.
5. Merck’s $11B Bet on Bio-Techne (https://www.reuters.com/business/healthcare-pharmaceuticals/germanys-merck-buy-bio-techne-73-per-share-2026-06-25/): In a massive expansion of its life sciences infrastructure, Germany’s Merck has announced an $11.3 billion acquisition of Bio-Techne. This deal is designed to scale Merck’s catalog of high-demand consumables—including hundreds of thousands of antibodies and proteins—further cementing their "picks and shovels" dominance in the precision diagnostics and cell therapy research markets.
6. Oblenio Bio’s $62M Series B (https://endpoints.news/autoimmune-disease-company-oblenio-bio-clinches-62m-in-series-b/): Autoimmune-focused biotech Oblenio Bio has clinched a $62 million Series B raise led by Pfizer Ventures. The funding is earmarked to advance their proprietary trispecific T-cell engager (TCE) platform, signaling continued venture interest in next-generation immunotherapies that can tackle complex, multi-target autoimmune conditions.
7. Lilly’s $1B Alzheimer’s Licensing Deal (https://www.biospace.com/deals/lilly-bets-up-to-1b-with-alzecure-in-search-for-next-alzheimers-act): Extending its aggressive 2026 acquisition strategy, Eli Lilly has signed a deal worth up to $1 billion with Swedish biotech AlzeCure Pharma. Lilly gains global rights to a preclinical small-molecule candidate designed as a gamma-secretase modulator, aiming to provide a next-generation approach to reducing toxic amyloid-beta plaque in the brain.
8. Roche bets $700M upfront on Nurix (https://www.fiercebiotech.com/biotech/roche-bets-700m-upfront-nurixs-late-phase-btk-degrader-set-lilly-showdown): Roche has made a massive strategic pivot in the hematology and immunology space, committing $700 million upfront—with up to $2.3 billion in total milestones—to partner with Nurix Therapeutics on their lead BTK degrader. This deal is a direct challenge to the current market standard, Eli Lilly’s Jaypirca, as the companies prepare for head-to-head Phase 3 trials. Unlike traditional kinase inhibitors, Nurix’s degrader physically eliminates the BTK protein, offering a potential "best-in-class" profile.

II. AI-Native Discovery & Tech-Bio Partnerships

1. Insilico Medicine’s $2.5B SK Biopharm Deal (https://www.fiercebiotech.com/biotech/insilico-lands-heavily-backloaded-25b-ai-drug-discovery-deal-sk-biopharm): Signaling the increasing integration of generative AI in high-stakes research, Insilico has landed a massive, heavily backloaded $2.5B R&D deal with SK Biopharmaceuticals. The collaboration is focused on accelerating the discovery of novel small molecules for complex neuroimmune disorders, aiming to compress development timelines significantly.
2. Antares Therapeutics & Novartis’ $1.9B Cancer Pact (https://www.reuters.com/legal/litigation/antares-therapeutics-signs-potential-19-billion-cancer-drug-deal-with-novartis-2026-06-24/): Newly-launched Antares has signed a potential $1.9 billion deal with Novartis to tackle "undruggable" oncology targets. By deploying its proprietary covalent discovery engine, Antares is positioning itself as a high-tech discovery partner for Big Pharma, which is increasingly eager to outsource high-risk, high-reward early research.
3. Alnylam’s $2B Inceptive Partnership (https://www.biospace.com/deals/alnylam-hops-on-ai-train-with-up-to-2b-inceptive-partnership): Alnylam is doubling down on its RNAi leadership by partnering with Inceptive. This collaboration integrates Inceptive’s foundation models and sequence-based AI design into Alnylam’s proprietary platform, marking a strategic move to optimize the discovery of "next-gen" nucleic acid medicines.
4. Novartis’ $1.4B Deal with Orionis (https://www.fiercebiotech.com/biotech/novartis-sticks-2nd-deal-molecular-glue-biotech-orionis-worth-14b): Novartis has deepened its ties to molecular glue technology through a $1.4B deal with Orionis. By leveraging Orionis’ platform, Novartis continues its pursuit of target-degradation strategies, which are increasingly seen as the most efficient way to modulate proteins that were previously considered unreachable.

III. Precision Medicine & Novel Modalities

1. J&J’s $1B Bet on Firefly Bio (https://www.fiercebiotech.com/biotech/jj-makes-1b-upfront-bet-emerging-dac-space-netting-firefly-bio): Johnson & Johnson has placed a $1B upfront bet to acquire Firefly Bio, diving headfirst into the emerging space of Degrader Antibody Conjugates (DACs). By combining the targeted precision of antibodies with the protein-degradation capability of DACs, J&J is attempting to overcome the efficacy ceilings encountered by standard ADCs.
2. Lilly’s $1.9B RNA Exon Editing Pact with Ascidian (https://www.fiercebiotech.com/biotech/ascidian-lilly-lock-19b-renal-disease-research-collaboration): Continuing its quest to own the future of genetic medicine, Lilly has signed a $1.9 billion deal to license Ascidian’s RNA exon-editing technology. This "DNA-free" approach to correcting inherited kidney diseases represents a safer, potentially more reversible alternative to traditional gene editing.
3. Lilly’s Strategic Metabolic Expansion (https://endpoints.news/lilly-licenses-glp-2-asset-from-korean-biotech-hanmi-for-75m-upfront/): Lilly is broadening its metabolic footprint through two new deals: entering the GLP-2 space via a partnership with Korea’s Hanmi, and forging a discovery pact with China’s Haisco. These moves indicate that Lilly is not just resting on its GLP-1 dominance but is aggressively building a diversified portfolio across the entire metabolic spectrum.

IV. IPOs, Financing & Corporate Restructuring

1. Parabilis’ Record-Breaking $670M IPO (https://www.fiercebiotech.com/biotech/cancer-focused-parabilis-upsized-670m-ipo-breaks-new-record-biotechs): In a clear sign of renewed investor appetite for cancer-focused biotechs, Parabilis has set a new record for the year, pulling in $670 million in an upsized IPO. This massive capital infusion underscores the market's high confidence in the firm's oncology pipeline.
2. Kardigan’s $400M IPO (https://www.fiercebiotech.com/biotech/kardigan-buttons-400m-upsized-ipo-power-heart-drugs-toward-phase-3): Proving that the "IPO drought" is officially over for high-quality assets, cardiovascular startup Kardigan successfully priced a $400 million IPO. The funding will power their heart-disease candidates into phase 3 trials, marking one of the largest cardiovascular-focused offerings in years.
3. Ethyreal Bio’s $101M Launch (https://www.fiercebiotech.com/biotech/ethyreal-bio-manifests-101m-pack-biotechs-gunning-amgens-tepezza): Ethyreal Bio has emerged from stealth with $101 million to take on the Tepezza standard of care. By developing a monoclonal antibody for Graves and thyroid eye disease, they aim to disrupt a market segment that has historically been dominated by high-cost, IV-administered treatments.
4. Pfizer’s $1.7B Cost-Savings Revamp (https://www.biospace.com/business/pfizer-announces-another-1-7b-in-cost-savings-including-r-d-revamp): Signaling a shift toward "leaner" operations, Pfizer has announced a further $1.7 billion in cost savings. The revamp involves a significant restructuring of its R&D organization, as the company works to shed legacy costs and optimize its focus on high-growth oncology and rare disease targets.
5. Takeda’s $2.5B Legal Provision (https://firstwordpharma.com/story/7530342): In a difficult quarter, Takeda has been pushed into the red after recording a $2.5B provision related to ongoing litigation. This hit serves as a sobering reminder of the financial volatility and "legacy risk" that can occasionally derail even the most robust commercial organizations.

The Biopharma Salary Landscape (https://endpoints.news/pharma-and-biotech-salaries-top-paying-companies-of-2025/): A recent analysis of 2025 pay data highlights the massive compensation gap in the sector: while the average biopharma worker earns ~30% more than the S&P 500 average, internal hierarchies vary wildly. Notably, lean, high-science biotech firms like Alnylam ($312k median) and Ionis ($305k median) are significantly outpaying traditional "Big Pharma" giants like J&J ($91k median), reflecting a shift in how talent is valued in the era of high-tech R&D.

With that, that is a wrap for June 2026 news.

This has been Petri Dish Perspectives. I’m Manead. I’ll be back next month with a recap for July. Thanks for listening. Goodbye!

© 2026 The Perspective Bureau LLC. All rights reserved.